Biblio

Export 2446 results:
Author Title Type [ Year(Desc)]
Filters: First Letter Of Keyword is A  [Clear All Filters]
2022
X. Hua, Church, K., Walker, W., L'Hostis, P., Viardot, G., Danjou, P., Hendrix, S., and Moebius, H. J., Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial., J Alzheimers Dis, vol. 86, no. 3, pp. 1399-1413, 2022.
X. Hua, Church, K., Walker, W., L'Hostis, P., Viardot, G., Danjou, P., Hendrix, S., and Moebius, H. J., Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial., J Alzheimers Dis, vol. 86, no. 3, pp. 1399-1413, 2022.
X. Hua, Church, K., Walker, W., L'Hostis, P., Viardot, G., Danjou, P., Hendrix, S., and Moebius, H. J., Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial., J Alzheimers Dis, vol. 86, no. 3, pp. 1399-1413, 2022.
A. Sil, Erfani, A., Lamb, N., Copland, R., Riedel, G., and Platt, B., Sex Differences in Behavior and Molecular Pathology in the 5XFAD Model., J Alzheimers Dis, vol. 85, no. 2, pp. 755-778, 2022.
A. Sil, Erfani, A., Lamb, N., Copland, R., Riedel, G., and Platt, B., Sex Differences in Behavior and Molecular Pathology in the 5XFAD Model., J Alzheimers Dis, vol. 85, no. 2, pp. 755-778, 2022.
A. Sil, Erfani, A., Lamb, N., Copland, R., Riedel, G., and Platt, B., Sex Differences in Behavior and Molecular Pathology in the 5XFAD Model., J Alzheimers Dis, vol. 85, no. 2, pp. 755-778, 2022.
S. Hannonen, Andberg, S., Kärkkäinen, V., Rusanen, M., Lehtola, J. - M., Saari, T., Korhonen, V., Hokkanen, L., Hallikainen, M., Hänninen, T., Leinonen, V., Kaarniranta, K., Bednarik, R., and Koivisto, A. M., Shortening of Saccades as a Possible Easy-to-Use Biomarker to Detect Risk of Alzheimer's Disease., J Alzheimers Dis, vol. 88, no. 2, pp. 609-618, 2022.
J. Lynn, Park, M., Ogunwale, C., and Acquaah-Mensah, G. K., A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer's Disease., J Alzheimers Dis, vol. 85, no. 2, pp. 485-501, 2022.
J. Lynn, Park, M., Ogunwale, C., and Acquaah-Mensah, G. K., A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer's Disease., J Alzheimers Dis, vol. 85, no. 2, pp. 485-501, 2022.
K. Metsla, Kirss, S., Laks, K., Sildnik, G., Palgi, M., Palumaa, T., Tõugu, V., and Palumaa, P., α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease., J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
K. Metsla, Kirss, S., Laks, K., Sildnik, G., Palgi, M., Palumaa, T., Tõugu, V., and Palumaa, P., α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease., J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
K. Metsla, Kirss, S., Laks, K., Sildnik, G., Palgi, M., Palumaa, T., Tõugu, V., and Palumaa, P., α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease., J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
K. Metsla, Kirss, S., Laks, K., Sildnik, G., Palgi, M., Palumaa, T., Tõugu, V., and Palumaa, P., α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease., J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
K. Metsla, Kirss, S., Laks, K., Sildnik, G., Palgi, M., Palumaa, T., Tõugu, V., and Palumaa, P., α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease., J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
K. Metsla, Kirss, S., Laks, K., Sildnik, G., Palgi, M., Palumaa, T., Tõugu, V., and Palumaa, P., α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease., J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
2023
J. Jia, Zhang, Y., Shi, Y., Yin, X., Wang, S., Li, Y., Zhao, T., Liu, W., Zhou, A., and Jia, L., A 19-Year-Old Adolescent with Probable Alzheimer's Disease., J Alzheimers Dis, vol. 91, no. 3, pp. 915-922, 2023.
J. Jia, Zhang, Y., Shi, Y., Yin, X., Wang, S., Li, Y., Zhao, T., Liu, W., Zhou, A., and Jia, L., A 19-Year-Old Adolescent with Probable Alzheimer's Disease., J Alzheimers Dis, vol. 91, no. 3, pp. 915-922, 2023.
J. Jia, Zhang, Y., Shi, Y., Yin, X., Wang, S., Li, Y., Zhao, T., Liu, W., Zhou, A., and Jia, L., A 19-Year-Old Adolescent with Probable Alzheimer's Disease., J Alzheimers Dis, vol. 91, no. 3, pp. 915-922, 2023.
J. Jia, Zhang, Y., Shi, Y., Yin, X., Wang, S., Li, Y., Zhao, T., Liu, W., Zhou, A., and Jia, L., A 19-Year-Old Adolescent with Probable Alzheimer's Disease., J Alzheimers Dis, vol. 91, no. 3, pp. 915-922, 2023.
N. Ortí-Casañ, Wajant, H., H Kuiperij, B., Hooijsma, A., Tromp, L., Poortman, I. L., Tadema, N., de Lange, J. H. E., Verbeek, M. M., De Deyn, P. P., Naudé, P. J. W., and Eisel, U. L. M., Activation of TNF Receptor 2 Improves Synaptic Plasticity and Enhances Amyloid-β Clearance in an Alzheimer's Disease Mouse Model with Humanized TNF Receptor 2., J Alzheimers Dis, vol. 94, no. 3, pp. 977-991, 2023.
N. Ortí-Casañ, Wajant, H., H Kuiperij, B., Hooijsma, A., Tromp, L., Poortman, I. L., Tadema, N., de Lange, J. H. E., Verbeek, M. M., De Deyn, P. P., Naudé, P. J. W., and Eisel, U. L. M., Activation of TNF Receptor 2 Improves Synaptic Plasticity and Enhances Amyloid-β Clearance in an Alzheimer's Disease Mouse Model with Humanized TNF Receptor 2., J Alzheimers Dis, vol. 94, no. 3, pp. 977-991, 2023.
N. Ortí-Casañ, Wajant, H., H Kuiperij, B., Hooijsma, A., Tromp, L., Poortman, I. L., Tadema, N., de Lange, J. H. E., Verbeek, M. M., De Deyn, P. P., Naudé, P. J. W., and Eisel, U. L. M., Activation of TNF Receptor 2 Improves Synaptic Plasticity and Enhances Amyloid-β Clearance in an Alzheimer's Disease Mouse Model with Humanized TNF Receptor 2., J Alzheimers Dis, vol. 94, no. 3, pp. 977-991, 2023.
D. L. Alkon, Sun, M. - K., Tuchman, A. J., and Thompson, R. E., Advanced Alzheimer's Disease Patients Show Safe, Significant, and Persistent Benefit in 6-Month Bryostatin Trial., J Alzheimers Dis, vol. 96, no. 2, pp. 759-766, 2023.
J. - Y. Liu, Ma, L. - Z., Wang, J., Cui, X. - J., Sheng, Z. - H., Fu, Y., Li, M., Ou, Y. - N., Yu, J. - T., Tan, L., and Lian, Y., Age-Related Association Between APOE ɛ4 and Cognitive Progression in de novo Parkinson's Disease., J Alzheimers Dis, vol. 91, no. 3, pp. 1121-1132, 2023.
J. - Y. Liu, Ma, L. - Z., Wang, J., Cui, X. - J., Sheng, Z. - H., Fu, Y., Li, M., Ou, Y. - N., Yu, J. - T., Tan, L., and Lian, Y., Age-Related Association Between APOE ɛ4 and Cognitive Progression in de novo Parkinson's Disease., J Alzheimers Dis, vol. 91, no. 3, pp. 1121-1132, 2023.

Pages